In June 2015, the FDA advisory committee endorsed the approval of flibanserin, a drug aimed at addressing hypoactive sexual desire disorder (HSDD) in women. Developed by Sprout Pharmaceuticals, the drug, later branded as Addyi, faced initial rejections due to concerns over safety and efficacy. Its ultimate approval marked a milestone in women’s sexual health, despite debates over its implications for gender equality in medical research.
Read more